Transcranial Magnetic Stimulation (TMS)

Overview

What TMS Is

A TMS device delivers brief, rapidly changing magnetic pulses through a coil placed against the scalp. Those pulses cross the skull without significant attenuation and induce small focal electric currents in the underlying cortex, depolarizing neurons. When pulses are delivered in trains and repeated daily over weeks, they produce lasting changes in cortical excitability and downstream brain circuits.

What It Is Not

TMS is not electroconvulsive therapy. It does not require anesthesia, does not induce a seizure as part of the treatment, does not cause amnesia, and does not require a hospital admission. It is also not a single procedure: a "course of TMS" means a series of treatments delivered over several weeks.

Variants in Use Today

• Repetitive TMS (rTMS): The original and still most common form. Standard high-frequency rTMS to the left dorsolateral prefrontal cortex (DLPFC) is the depression workhorse.
• Deep TMS (dTMS): Uses the H-coil (developed by Brainsway) to reach deeper and broader cortical regions. Cleared for depression, OCD, smoking cessation, and anxious depression.
• Theta burst stimulation (TBS): Delivers bursts of three high-frequency pulses repeated at theta rhythm (about 5 Hz). Intermittent TBS (iTBS) is excitatory; continuous TBS (cTBS) is inhibitory. iTBS to the left DLPFC produces depression outcomes comparable to standard rTMS in shorter sessions.
• Accelerated TMS: Multiple sessions per day delivered over several days, sometimes with functional MRI targeting. The Stanford Neuromodulation Therapy (SNT, originally SAINT) protocol is the best-known example.

Who Delivers TMS

TMS is prescribed and supervised by a physician, typically a psychiatrist, and administered day-to-day by trained TMS technicians. A medical evaluation, motor threshold determination, and informed consent precede treatment.

Historical Origins

Early Electromagnetism and the Nervous System

The principle that a changing magnetic field can induce electrical activity dates to Faraday in 1831. Through the late 19th and 20th centuries, scientists experimented with magnetic stimulation of nerves and muscles, but generating fields strong and fast enough to depolarize cortical neurons through the skull required modern capacitor technology.

Barker's First Cortical Stimulation

The defining moment came in 1985, when Anthony Barker and colleagues at the University of Sheffield demonstrated focal magnetic stimulation of the human motor cortex in awake subjects, producing visible muscle twitches in the opposite hand. Unlike earlier transcranial electrical stimulation, the magnetic technique was painless. The first generation of clinical and research TMS devices followed.

Repetitive Stimulation and Mood Effects

Through the 1990s, researchers explored whether repeated trains of pulses to specific cortical regions could produce lasting clinical effects, particularly in depression. Mark George and colleagues at NIH and the Medical University of South Carolina conducted some of the foundational trials targeting the left DLPFC.

FDA Clearances

In 2008, the FDA cleared NeuroStar's figure-8 coil rTMS device for treatment-resistant major depressive disorder. Brainsway's H-coil deep TMS received depression clearance in 2013. The pipeline expanded over the next decade: deep TMS for OCD (2018), deep TMS for smoking cessation (2020), various devices cleared for anxious depression, and adolescent indications more recently. Theta burst protocols and accelerated SNT-style approaches followed in the early 2020s.

Beyond Psychiatry

TMS is also used in neurology and rehabilitation — for post-stroke recovery, neuropathic pain, and migraine — though psychiatric indications remain the largest clinical application. Research-only uses include exploration of schizophrenia auditory hallucinations, PTSD, and substance use disorders.

How It Works

The Physics

A TMS device stores energy in a capacitor and discharges it through an electromagnetic coil in a few hundred microseconds. The discharge creates a brief magnetic field — peaking around 1.5 to 2.5 Tesla, comparable in strength to an MRI scanner — directed perpendicular to the coil. The field passes through hair, skin, skull, and meninges essentially unimpeded and induces an electric field in conductive tissue. Where that induced field is strong enough, neurons depolarize.

Coil Geometry and Focality

The figure-8 coil (two overlapping circular windings) produces a relatively focal stimulation peak — typically a few cubic centimeters — at the cortical surface beneath the intersection. The H-coil used in deep TMS is larger and more complex, producing a broader, deeper field at the cost of focality. No clinical TMS coil reaches deep subcortical structures such as the amygdala or hippocampus directly; deeper effects are produced indirectly through cortical networks.

The Standard Depression Target

For depression, the most common target is the left dorsolateral prefrontal cortex. This region is hypoactive in depression on average and is anatomically connected to limbic and subcortical structures involved in mood regulation. High-frequency stimulation (typically 10 Hz) at this site is excitatory and is thought to upregulate prefrontal-limbic circuits. Some protocols target the right DLPFC with low-frequency (1 Hz) inhibitory stimulation, alone or in combination.

The OCD Target

For OCD, deep TMS targets the medial prefrontal cortex and anterior cingulate, regions implicated in the cortico-striatal-thalamic loops thought to underlie obsessions and compulsions. Treatment is typically delivered after OCD symptom provocation.

Why Repeated Sessions

A single TMS session has only transient cortical effects. Daily stimulation across several weeks is thought to induce neuroplastic changes — long-term potentiation-like and long-term depression-like processes — that durably alter circuit function. Treatment effects in depression generally accumulate over the first three to four weeks of a course.

Motor Threshold and Dosing

Before treatment begins, the clinician determines the patient's motor threshold by stimulating the motor cortex and identifying the minimum intensity that produces a visible thumb twitch. Treatment intensity is set as a percentage of this threshold (commonly 120% for high-frequency depression protocols), individualizing dose to each patient's cortical excitability.

Targeting Precision

Original protocols located the DLPFC by measuring forward from the motor cortex (the so-called "5 cm rule"). MRI-guided neuronavigation and connectivity-based targeting — used in SNT and many research protocols — improve precision and are associated with better outcomes in some studies.

What a Typical Course Involves

Standard rTMS for Depression

The classical protocol involves daily weekday sessions for 4 to 6 weeks, often followed by a 1 to 2 week taper. Each session lasts about 30 to 40 minutes. The patient sits awake in a reclining chair while the coil delivers trains of pulses to the targeted scalp location. Patients can typically drive themselves home and return to work the same day.

Intermittent Theta Burst (iTBS)

An iTBS session takes about 3 minutes of stimulation time and is delivered daily on a similar weekday schedule. Total time at the clinic is shorter than standard rTMS, and clinical outcomes are comparable on average. iTBS has become a common default in many practices.

Deep TMS

Deep TMS sessions using the H-coil take about 20 minutes for depression and a similar timeframe for OCD, with the OCD protocol preceded by individualized symptom provocation. Courses are typically 4 to 6 weeks of weekday sessions.

Accelerated Protocols (SNT/SAINT)

The Stanford Neuromodulation Therapy protocol delivers up to ten iTBS sessions per day, spaced about an hour apart, over five consecutive days. Targets are individualized by functional MRI connectivity. Initial trial outcomes in severe treatment-resistant depression have been striking, though replication and broader rollout are ongoing. Accelerated protocols are particularly attractive for hospitalized patients or those who cannot commit to weeks of daily outpatient visits.

Maintenance and Re-Treatment

Many patients who respond to an initial course experience eventual relapse. Practices vary: some offer periodic single-session "boosters," some re-treat with a tapered re-induction at the first signs of return, and others rely on antidepressants for maintenance with TMS reserved for relapse. Insurance coverage of maintenance is inconsistent.

The In-Session Experience

Patients hear a loud clicking sound with each pulse and wear earplugs. They feel a tapping or pecking sensation on the scalp under the coil, sometimes facial muscle twitching. Many read, watch shows, or chat with the technician during treatment. The clinician will check in periodically about tolerability and adjust intensity if needed.

Conditions Treated and Evidence Base

Major Depressive Disorder

TMS has the strongest evidence base in treatment-resistant unipolar major depression. Across many randomized sham-controlled trials and large naturalistic studies, response rates run in the 40 to 60% range and remission rates around 30 to 40% in patients who have failed at least one antidepressant. Effects are larger in less treatment-resistant patients and smaller — but still meaningful — in those with multiple prior failures. iTBS appears non-inferior to standard rTMS in the largest head-to-head trials.

Anxious Depression

Many depressed patients have prominent anxiety; specific TMS protocols and devices have been cleared for this presentation, with evidence suggesting comparable or slightly better outcomes than standard depression rTMS for patients with high baseline anxiety.

Obsessive-Compulsive Disorder

Deep TMS to the medial prefrontal cortex and anterior cingulate was FDA-cleared for OCD in 2018 on the basis of a multisite trial showing meaningful symptom reduction compared with sham. Response rates are more modest than for depression (often around 30 to 40% with strict criteria), but for severe, treatment-resistant OCD this is a clinically valuable option.

Smoking Cessation

Deep TMS received FDA clearance in 2020 for adults seeking to quit smoking, based on trials showing improved continuous abstinence rates over sham. It is one of the few biologically based interventions cleared for tobacco use disorder beyond nicotine replacement and pharmacotherapy.

Adolescent Depression

Adolescent indications have been added more recently for major depression, after open-label and randomized data suggested efficacy and acceptable tolerability in patients 15 and older.

Bipolar Depression

Evidence is more mixed. TMS is sometimes used cautiously in bipolar depression with concurrent mood-stabilizer coverage to reduce the (small) risk of treatment-emergent mania. It is not as well established here as in unipolar depression.

PTSD, Generalized Anxiety, Substance Use

Research is active but evidence is preliminary. Some protocols target the right DLPFC for PTSD; others target craving circuits for substance use disorders. None of these has the regulatory and evidentiary weight of the cleared indications.

Neurological Indications

Outside psychiatry, TMS is used or studied in post-stroke motor recovery, chronic neuropathic pain, fibromyalgia, migraine (with specific devices), and tinnitus. Evidence varies by indication.

Risks and Side Effects

Common Side Effects

• Scalp pain or discomfort at the stimulation site (most common; usually mild and decreases over the first sessions)
• Headache, particularly in the first week
• Facial muscle twitching during stimulation
• Lightheadedness
• Fatigue after sessions in some patients

Seizure Risk

Induced seizure is the most serious potential adverse event. Estimated risk with modern protocols is on the order of one in tens of thousands of sessions and is very rare in adherence to published safety guidelines. Risk factors include personal or family history of epilepsy, certain medications that lower seizure threshold, alcohol or benzodiazepine withdrawal, and sleep deprivation. Pre-treatment screening explicitly looks for these.

Treatment-Emergent Mania

In bipolar patients, TMS can — rarely — precipitate hypomania or mania. Adequate mood-stabilizer coverage and clinical monitoring address this risk.

Hearing

TMS coils produce a loud click during discharge. Earplugs are mandatory; hearing problems are very rare with their use.

Cognitive Effects

Unlike ECT, TMS does not impair memory or cognition. Some patients report mild post-session fogginess that resolves quickly; others report subjective improvement in concentration as depression remits.

Contraindications

• Implanted metallic or magnetic-sensitive devices within roughly 30 cm of the coil — including cochlear implants, deep brain stimulators, vagus nerve stimulators, and aneurysm clips
• Some dental and surgical hardware in the head (case-by-case assessment)
• Active or unstable seizure disorder (relative)
• Pregnancy is not a strict contraindication for TMS targeting the prefrontal cortex, but informed consent and obstetric coordination are required

What Is Not a Contraindication

Dental fillings, orthodontic braces, and most spinal hardware are far enough from the coil to be safe. A history of childhood febrile seizure alone is not a strict contraindication but is discussed in screening.

Cost, Access, and Insurance

List Pricing

The retail price of a full course of TMS for depression in the United States typically runs between $10,000 and $15,000, with some accelerated and research-protocol courses costing more. Individual sessions are generally billed in the few-hundred-dollar range; total cost depends on protocol length.

Insurance Coverage

Commercial insurance, Medicare, and many Medicaid plans now cover TMS for major depressive disorder when criteria are met. Typical criteria include a confirmed diagnosis, failure of an adequate trial of one or more antidepressants (often four or more), and no contraindications. OCD coverage is less uniform but expanding. Smoking cessation and off-label indications are often not covered.

The Prior-Authorization Process

Even with coverage, patients usually go through prior authorization, which can take days to weeks. TMS centers generally handle the paperwork. Patients should ask about expected out-of-pocket cost, copays per session, and whether maintenance treatment will be covered if needed later.

Access

TMS centers are concentrated in metropolitan areas. The daily-attendance requirement is a real barrier for working people, parents, and rural residents. Accelerated protocols, telepsychiatry-supported follow-up, and the spread of theta burst (which dramatically shortens session time) are gradually improving access.

Choosing a Provider

Reasonable questions to ask include: who is the supervising physician, how is targeting determined, what device and protocol are used, how is response measured, what is the practice's experience with similar patients, and what happens if you do not respond after a few weeks. Outcomes vary across centers.

Comparison with Alternative Treatments

TMS Versus Antidepressant Medication

For uncomplicated, less treatment-resistant depression, antidepressants are first-line on grounds of access, cost, and the larger evidence base. TMS becomes attractive after one or more antidepressant failures, in patients intolerant to antidepressant side effects, and in patients who prefer a non-systemic treatment. TMS can also be added to ongoing medication.

TMS Versus ECT

ECT remains more effective than TMS for the most severe, life-threatening depression, particularly with psychotic features, catatonia, or extreme suicidality. ECT requires anesthesia, has more cognitive side effects, and carries social stigma. TMS is less invasive, has fewer side effects, and does not require anesthesia or driving restriction. For patients who can wait several weeks for response and whose depression is not life-threatening, TMS is generally tried before ECT. See our ECT page for direct comparison.

TMS Versus Ketamine and Esketamine

Intranasal esketamine (FDA-approved 2019) and IV ketamine are alternative options for treatment-resistant depression with faster onset (hours to days) but generally less durable single-dose effects and a different side-effect profile (dissociation, sedation, abuse potential). Some patients alternate or combine modalities.

TMS Versus Other Neuromodulation

• Vagus nerve stimulation (VNS): Invasive implanted device, FDA-approved for treatment-resistant depression but slower onset and surgical risks.
• Deep brain stimulation (DBS): Investigational for severe treatment-resistant depression and OCD. Invasive and largely research-restricted in psychiatric use.
• Transcranial direct current stimulation (tDCS): Lower-cost, weaker stimulation. Some evidence in depression but not FDA-cleared and not equivalent to TMS in efficacy.

TMS Versus Psychotherapy

Psychotherapy and TMS address depression through different routes and are not mutually exclusive. Many patients pursue both. Psychotherapy alone is appropriate for many depressions, especially milder presentations and those tied closely to life circumstances, trauma, or maladaptive cognitive patterns.

Limitations and Controversies

Not Everyone Responds

Even in the best-case populations, a substantial fraction of patients (often 40 to 50%) do not respond meaningfully to a standard TMS course. Predictors of response remain imperfect: shorter illness duration, less treatment resistance, and higher baseline anxiety symptoms are among the modest predictors. Patient selection should be honest about the realistic probabilities.

Durability

Relapse within a year is common even among responders. The optimal long-term strategy — maintenance TMS, antidepressants, psychotherapy, or some combination — is not fully established. This is an active research area.

Sham Controls and Blinding

Designing convincing sham TMS is hard. Active stimulation produces scalp sensation, twitches, and sound that placebo coils do not perfectly mimic. Some patients can correctly guess their assignment, which can inflate apparent treatment effects in unblinded comparisons. Modern trials have improved sham coils, but the issue is not fully resolved.

Off-Label and Wellness Use

TMS is sometimes marketed for indications without strong evidence — cognitive enhancement, generalized anxiety, attention, "brain fog" — at premium prices. Consumers should be skeptical of claims that outrun the published trial literature.

Mechanism Uncertainty

Although TMS clearly changes cortical excitability and downstream activity, the precise mechanism by which it produces lasting clinical improvement is not fully worked out. Network-level changes, neuroplastic synaptic changes, and indirect effects on neurotransmitter systems all appear involved.

Equity

TMS is concentrated in well-resourced settings, and the daily-attendance model historically favored patients with flexible schedules and nearby clinics. Theta burst, accelerated protocols, and broader insurance coverage are gradually broadening reach, but equity gaps remain.

Quality Variability

Outcomes depend on targeting precision, motor-threshold determination, coil placement, session adherence, and clinician experience. Two TMS centers can produce noticeably different response rates. Accreditation programs exist (such as those run by clinical TMS societies), and patients can ask about training and outcomes.

What to Expect

Evaluation

A psychiatric evaluation establishes the diagnosis, treatment history, and suitability for TMS. The clinician reviews medications, implanted devices, seizure history, and relevant medical conditions, and discusses the realistic probability of response.

First Session

The first session usually includes motor threshold determination, target localization, and a few minutes of stimulation. Patients can expect a loud clicking sound, scalp tapping sensation, and possibly facial twitching. Earplugs are provided. The session is awake and outpatient.

Across the Course

Sessions are scheduled five days a week for several weeks. Most patients tolerate them well after the first week. Some notice gradual improvement in sleep, energy, or motivation before mood lifts; others feel unchanged for two or three weeks and then improve. A minority do not improve.

Measurement

Reputable centers use standardized depression rating scales (such as PHQ-9 or MADRS) at intake and at intervals during treatment to track progress objectively rather than relying on impression alone.

After the Course

Responders typically continue with antidepressants, psychotherapy, or a maintenance plan. Re-treatment with TMS upon relapse is common and often as effective as the first course. Non-responders may consider another protocol, ECT, ketamine, or further pharmacological options.

Day-to-Day Logistics

• No driving restriction after sessions
• No anesthesia or fasting required
• You can take your usual medications
• You can wear regular clothing; jewelry near the head is removed
• Caffeine and meal timing are generally unrestricted